Celldex Therapeutics Inc (CLDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.26B
Last updated: Nov 17, 2026 at 11:05 AM ET
Celldex Therapeutics Inc (CLDX) Earnings: Report Dates and Results
Celldex Therapeutics (CLDX) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Celldex Therapeutics reported EPS of -$0.96, above the -$1.02 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CLDX has an expected report date of Feb 23, 2027.
Earnings History
Of the 40 quarters below that had an estimate, CLDX beat 23, missed 16 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2018, when EPS landed 315.84% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.96 | -$1.02 | -$1.07 - -$0.94 | +5.88% | Beat | N/A | 10 | N/A | Nov 5, 2026 | N/A |
| Jun 30, 2026 | -$0.94 | -$1.04 | -$1.16 - -$0.92 | +9.62% | Beat | N/A | 10 | 4 up, 0 down | Aug 6, 2026 | $22000 |
| Mar 31, 2026 | -$1.18 | -$1.13 | -$1.32 - -$0.35 | -4.42% | Miss | N/A | 10 | N/A | May 7, 2026 | $15000 |
| Dec 31, 2025 | -$1.22 | -$1.00 | -$1.13 - -$0.89 | -22.00% | Miss | N/A | 12 | 0 up, 5 down | Feb 25, 2026 | $120000 |
| Sep 30, 2025 | -$1.01 | -$0.89 | -$0.99 - -$0.86 | -13.48% | Miss | N/A | 12 | 1 up, 4 down | Nov 10, 2025 | N/A |
| Jun 30, 2025 | -$0.85 | -$0.86 | -$0.95 - -$0.76 | +1.16% | Beat | N/A | 10 | 1 up, 8 down | Aug 7, 2025 | $730000 |
| Mar 31, 2025 | -$0.81 | -$0.74 | -$0.92 - -$0.59 | -9.46% | Miss | N/A | 10 | 1 up, 1 down | May 8, 2025 | $695000 |
| Dec 31, 2024 | -$0.71 | -$0.71 | -$0.87 - -$0.53 | +0.64% | Beat | N/A | 9 | 1 up, 3 down | Feb 27, 2025 | $1.18M |
| Sep 30, 2024 | -$0.64 | -$0.67 | -$0.75 - -$0.58 | +4.48% | Beat | N/A | 11 | 0 up, 0 down | Nov 6, 2024 | $3.19M |
| Jun 30, 2024 | -$0.54 | -$0.59 | -$0.67 - -$0.51 | +8.47% | Beat | N/A | 9 | 0 up, 0 down | Aug 8, 2024 | $2.50M |
| Mar 31, 2024 | -$0.56 | -$0.67 | -$0.75 - -$0.65 | +16.42% | Beat | N/A | 5 | 0 up, 0 down | May 6, 2024 | $156000 |
| Dec 31, 2023 | -$0.83 | -$0.74 | -$0.92 - -$0.49 | -12.16% | Miss | N/A | 8 | 1 up, 0 down | Feb 26, 2024 | $4.13M |
| Sep 30, 2023 | -$0.81 | -$0.66 | -$0.75 - -$0.62 | -22.73% | Miss | N/A | 7 | 0 up, 0 down | Nov 2, 2023 | $1.52M |
| Jun 30, 2023 | -$0.65 | -$0.66 | -$0.72 - -$0.63 | +1.52% | Beat | N/A | 6 | 0 up, 0 down | Aug 8, 2023 | $268000 |
| Mar 31, 2023 | -$0.62 | -$0.60 | -$0.66 - -$0.60 | -3.33% | Miss | N/A | 5 | 0 up, 0 down | May 4, 2023 | $967000 |
| Dec 31, 2022 | -$0.56 | -$0.59 | -$0.61 - -$0.56 | +5.08% | Beat | N/A | 6 | 0 up, 0 down | Feb 28, 2023 | $1.61M |
| Sep 30, 2022 | -$0.57 | -$0.57 | -$0.59 - -$0.55 | 0.00% | In line | N/A | 6 | 0 up, 0 down | Nov 9, 2022 | $407000 |
| Jun 30, 2022 | -$0.58 | -$0.42 | N/A | -38.10% | Miss | N/A | N/A | 0 up, 0 down | Aug 8, 2022 | $163000 |
| Mar 31, 2022 | -$0.50 | -$0.43 | -$0.49 - -$0.43 | -16.28% | Miss | N/A | 5 | 0 up, 0 down | May 5, 2022 | $174000 |
| Dec 31, 2021 | -$0.43 | -$0.42 | -$0.47 - -$0.38 | -2.38% | Miss | N/A | 6 | N/A | Feb 28, 2022 | $333000 |
| Sep 30, 2021 | -$0.37 | -$0.35 | -$0.42 - -$0.32 | -5.71% | Miss | N/A | 6 | N/A | Nov 9, 2021 | $153000 |
| Jun 30, 2021 | -$0.34 | -$0.40 | -$0.43 - -$0.37 | +15.00% | Beat | N/A | 4 | N/A | Aug 5, 2021 | $3.48M |
| Mar 31, 2021 | -$0.42 | -$0.37 | N/A | -13.51% | Miss | N/A | N/A | N/A | May 6, 2021 | $685000 |
| Dec 31, 2020 | -$0.55 | -$0.37 | -$0.38 - -$0.35 | -48.65% | Miss | N/A | 3 | N/A | Mar 29, 2021 | $3.79M |
| Sep 30, 2020 | -$0.36 | -$0.38 | -$0.38 - -$0.34 | +5.26% | Beat | N/A | 2 | N/A | Nov 5, 2020 | $668000 |
| Jun 30, 2020 | -$0.57 | -$0.58 | -$0.77 - -$0.39 | +1.72% | Beat | N/A | 2 | N/A | Aug 6, 2020 | $236000 |
| Mar 31, 2020 | -$0.73 | -$0.72 | -$0.72 - -$0.70 | -1.39% | Miss | N/A | 2 | N/A | May 6, 2020 | $2.73M |
| Dec 31, 2019 | -$0.64 | -$0.90 | -$0.93 - -$0.87 | +28.89% | Beat | N/A | 2 | N/A | Mar 26, 2020 | $887000 |
| Sep 30, 2019 | -$0.75 | -$0.84 | -$0.84 - -$0.84 | +10.71% | Beat | N/A | 1 | N/A | Nov 12, 2019 | $546000 |
| Jun 30, 2019 | -$0.84 | -$1.17 | -$1.17 - -$1.17 | +28.21% | Beat | N/A | 1 | N/A | Aug 7, 2019 | $715000 |
| Mar 31, 2019 | -$1.40 | -$1.14 | -$1.14 - -$1.14 | -22.81% | Miss | N/A | 1 | N/A | May 7, 2019 | $1.43M |
| Dec 31, 2018 | -$0.81 | -$1.20 | -$1.20 - -$1.20 | +32.50% | Beat | N/A | 1 | N/A | Mar 7, 2019 | $1.77M |
| Sep 30, 2018 | -$0.60 | -$2.55 | -$2.55 - -$1.05 | +76.47% | Beat | N/A | 3 | N/A | Nov 7, 2018 | $941000 |
| Jun 30, 2018 | -$1.65 | -$2.70 | -$2.70 - -$1.20 | +38.89% | Beat | N/A | 3 | N/A | Aug 8, 2018 | $2.76M |
| Mar 31, 2018 | -$12.60 | -$3.03 | -$4.05 - -$1.65 | -315.84% | Miss | N/A | 5 | N/A | May 10, 2018 | $4.07M |
| Dec 31, 2017 | -$2.55 | -$3.71 | -$5.10 - -$2.85 | +31.27% | Beat | N/A | 7 | N/A | Mar 7, 2018 | $3.46M |
| Sep 30, 2017 | -$3.00 | -$4.01 | -$4.50 - -$3.45 | +25.19% | Beat | N/A | 6 | N/A | Nov 7, 2017 | $3.92M |
| Jun 30, 2017 | -$3.45 | -$4.17 | -$5.10 - -$3.45 | +17.27% | Beat | N/A | 7 | N/A | Aug 8, 2017 | $3.83M |
| Mar 31, 2017 | -$4.20 | -$4.31 | N/A | +2.55% | Beat | N/A | N/A | N/A | May 9, 2017 | $1.53M |
| Dec 31, 2016 | -$4.50 | -$5.04 | N/A | +10.71% | Beat | N/A | N/A | N/A | Mar 14, 2017 | $1.87M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.89, after -$2.45 the year before. It was -$18.90 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.89 | N/A |
| Dec 31, 2024 | -$2.45 | N/A |
| Dec 31, 2023 | -$2.91 | N/A |
| Dec 31, 2022 | -$2.21 | N/A |
| Dec 31, 2021 | -$1.56 | N/A |
| Dec 31, 2020 | -$2.21 | N/A |
| Dec 31, 2019 | -$3.63 | N/A |
| Dec 31, 2018 | -$15.66 | N/A |
| Dec 31, 2017 | -$13.20 | N/A |
| Dec 31, 2016 | -$18.90 | N/A |
Frequently Asked Questions About CLDX
When is Celldex Therapeutics's next earnings date?
Celldex Therapeutics's next earnings report is expected for Feb 23, 2027.
Did CLDX beat earnings estimates last quarter?
Yes. Celldex Therapeutics reported EPS of -$0.96 for the quarter ended Sep 30, 2026, above the -$1.02 estimate, a 5.88% surprise.
What EPS do analysts expect from CLDX next quarter?
The consensus EPS estimate for Celldex Therapeutics for the quarter ending Dec 31, 2026 is -$1.06 from 15 analysts, with estimates from -$1.10 to -$0.97.
How often does CLDX beat earnings estimates?
Celldex Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -4.01%.
CLDX pages: Overview, Earnings, Forecast, Financials, Competitors